<DOC>
	<DOCNO>NCT00532974</DOCNO>
	<brief_summary>The use Bioject 2000 needle free injection device ( NFID ) compress immunization schedule safely tolerate augment immunogenicity HIV-1 CTL epitope DNA vaccine ( EP1090 ) HIV-1 infected individual receive potent combination antiretroviral therapy ( ART ) undetectable level viral replication plasma .</brief_summary>
	<brief_title>A Phase 1 Safety Immunogenicity Study Epitope Based DNA Vaccine ( EP HIV-1090 ) HIV-1 Infected Individuals Receiving Antiretroviral Therapy ( ART )</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>HIV1 Infection CD4 Tcell count &gt; 350 HIV1 RNA level &lt; 400 copy Negative HbsAg antiHCV antibody Recent receipt experimental HIV1 vaccine Recent use immunomodulatory agent Hypersensitivity serious reaction study vaccine component Active opportunistic infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>HIV</keyword>
	<keyword>Human Immunodeficiency Virus</keyword>
	<keyword>Vaccines</keyword>
	<keyword>HIV Vaccines</keyword>
	<keyword>Peptide</keyword>
	<keyword>Peptide Vaccines</keyword>
	<keyword>HIV 1</keyword>
</DOC>